Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 17

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 17
---
 the Securities Purchase Agreements and the Consultant Warrants have a term of five years from the date of issuance.

Build &Build, LLC

On October 19, 2025,
we formed Build & Build, LLC, a Delaware limited liability company and a 100% owned subsidiary of the Company (“Build &
Build”), in connection with our BNB Strategy. Pursuant to our BNB Strategy, Build & Build will be used to house the cryptocurrency
assets of the Company.

| S-7 |

Our Nucleic-Acid Production Solutions

Our nucleic-acid production solutions enable the
rapid and efficient cell-free manufacturing of high-quality DNA and RNA, which are essential components for a new generation of advanced
biotherapeutics such as gene therapies, personalized medicine, adoptive cell therapies and messenger RNA (“mRNA”) and deoxyribonucleic
acid (“DNA”)-based vaccines, as well as in vitro diagnostic (“IVD”) applications.

The Company has developed three distinct and complementary
technology solutions:

| · | LineaDNA™: A proprietary, cell-free DNA production system that uses a large-scale polymerase chain reaction (PCR) process. This technology allows for the rapid and efficient production of high-fidelity synthetic DNA without the use of living cells. The resulting DNA can be used in the manufacturing of various biotherapeutics, serve as the starting material for mRNA therapeutics and vaccines, and as a critical component of IVDs. |

| · | LineaRNAP™: A next-generation RNA polymerase (“RNAP”) used to transform DNA into mRNA. Our RNAP is engineered with a patented DNA-binding domain that we believe results in high mRNA yields and reduced double-stranded RNA (dsDNA) contamination, a common problematic byproduct produced during mRNA production. |

| · | LineaIVT™: An integrated system that combines the Company’s LineaDNA and LineaRNAP technologies. This innovative solution simplifies the mRNA production workflow resulting in a streamlined production process with fewer impurities than traditional methods. |

Our business strategy is to continue advancing
our nucleic acid production solutions to support potential future sales and/or licensing agreements with third-party partners.

LineaDNA

LineaDNA is our core enabling technology for rapid,
efficient, and scalable cell-free manufacture of high-fidelity synthetic DNA sequences used in the manufacturing of a broad range of biotherapeutics.
The LineaDNA platform enzymatically produces a linear form of synthetic DNA we call “LineaDNA” that is an alternative to